Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?

Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (LLY -1.85%) is already giving Novo Nordisk (NVO -2.58%) a run for its money with the approval in the fourth quarter of 2023 of Zepbound. Now another rival could be on the way.Viking Therapeutics (VKTX -3.77%) announced results last week from a phase 2 clinical study of VK2735 in helping patients lose weight. Its share price promptly skyrocketed more than 130%. Is Viking Therapeutics stock a better buy than Eli L ...